Shopping Cart

Your shopping cart is currently empty

Strontium ranelate

Name: Strontium ranelate
Brand: TargetMol
SKU: T1641
Price: 40 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: S12911, Distrontium renelate) Copy Product Info

😃Good

Synonyms: S12911, Distrontium renelate

Catalog No. T1641 Copy Product Info

Purity: 98.97%

😃Good

Strontium ranelate (S12911), a strontium (II) salt of the ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in the treatment of severe osteoporosis.

Cas No. 135459-87-9

Pack Size	Price	USA Stock	Global Stock
25 mg	$40	In Stock	In Stock
50 mg	$56	In Stock	In Stock
100 mg	$81	In Stock	In Stock
500 mg	$247	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98.97%

Appearance:Solid

Color:White

Resource Download

COA LCMS

Product Introduction

Strontium ranelate AI Summary

Strontium ranelate exhibits multiple bioactivities across different models and assays. It has demonstrated a protective effect against H2O2-induced apoptosis in rat MC3T3-E1 cells, showing 8.83% protection for late apoptotic cells and 1.61% for early apoptotic cells. It is also an inhibitor of various human transporters (BSEP, MRP2, MRP3, and MRP4), albeit with low potency (IC50 > 133000.0 nM). The compound shows antiviral activity, particularly against SARS-CoV-2, by inhibiting cytotoxicity in both Caco-2 and VERO-6 cells, with an inhibition rate of 23.33% in Caco-2 cells at 10 µM over 48 hours, but with minimal activity (0.1% inhibition) in VERO-6 cells. Additionally, it inhibits the SARS-CoV-2 3CL-Pro protease by 7.66% at 20 µM. Strontium ranelate also displays inhibitory activity on human HDAC6, with 24.99% inhibition using a commercial peptide substrate, though this activity decreases significantly to 0.91% with a custom peptide substrate. These various activities suggest its potential role in mitigating oxidative stress, viral cytotoxicity, and enzyme inhibition..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Strontium ranelate (S12911), a strontium (II) salt of the ranelic acid, is a medication for osteoporosis. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in the treatment of severe osteoporosis.
Targets & IC50	Ca2+ channel:0.5 mM
Synonyms	S12911, Distrontium renelate

Chemical Properties

Molecular Weight	513.49
Formula	C₁₂H₆N₂O₈S·2Sr
Cas No.	135459-87-9
Smiles	[Sr+2].c1(c(c(c(s1)N(CC(=O)[O-])CC(=O)[O-])C#N)CC(=O)[O-])C(=O)[O-].[Sr+2]
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 10.53 mg/mL (20.51 mM), when pH is adjusted to 3 with HCl.

0.1 M HCL: 19.8 mg/mL (38.56 mM), Sonication is recommended.

H2O: Insoluble

Solution Preparation Table

DMSO/0.1 M HCL

	1mg	5mg	10mg	50mg
1 mM	1.9475 mL	9.7373 mL	19.4746 mL	97.3729 mL
5 mM	0.3895 mL	1.9475 mL	3.8949 mL	19.4746 mL
10 mM	0.1947 mL	0.9737 mL	1.9475 mL	9.7373 mL
20 mM	0.0974 mL	0.4869 mL	0.9737 mL	4.8686 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc